Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Olaparib · 1 trial · 4 indications
Overall Survival is defined as the time (in months) from the date of randomization to the date of death by any cause.
| Arm | Type | Description |
|---|---|---|
| Experimental Arm: IMNN-001 + SOC Chemotherapy + SOC Maintenance Therapy | EXPERIMENTAL | IMNN-001 in combination with standard neoadjuvant and adjuvant chemotherapy followed by standard of care maintenance therapy |
| Control Arm: SOC Chemotherapy + SOC Maintenance Therapy | ACTIVE_COMPARATOR | Standard neoadjuvant and adjuvant chemotherapy followed by standard of care maintenance therapy. |
| Name | Type | Description |
|---|---|---|
| IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) | DRUG | 100 mg/m2 IP given weekly during frontline treatment |
| Paclitaxel | DRUG | 175 mg/m2 IV given every 21 days for 6 cycles during frontline treatment |
| Carboplatin | DRUG | AUC 6 IV given every 21 days for 6 cycles during frontline treatment |
| Olaparib | DRUG | Olaparib (300 mg orally every 12 hours for 2 years) for patients with somatic or germline BRCAmut. |
| Niraparib | DRUG | Niraparib (200-300 mg orally daily for 3 years; dosing based on participant's weight and platelet counts) for either HRD/BRCAmut \& HRD/BRCAwt. |
Inclusion Criteria: 1. Participants must be female, ≥18 years of age, able to understand the study procedures, and agree to participate in the study by providing written informed consent. 2. Participants with a histologically confirmed diagnosis of high-grade non-mucinous epithelial ovarian (serous...
Olaparib is an investigational small molecule being studied for the treatment of epithelial ovarian cancer. It is currently in Phase 3 clinical development, evaluated in combination with standard neoadjuvant chemotherapy and adjuvant chemotherapy in newly diagnosed patients with advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Olaparib targets PARP1, PARP2, and PARP3, which are poly (ADP-ribose) polymerase enzymes. It acts as an inhibitor of these targets, a mechanism being studied in the context of epithelial ovarian cancer treatment.
Olaparib is being developed by Imunon, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol IMNN. The company is conducting a Phase 3 clinical trial of Olaparib for the treatment of epithelial ovarian cancer.
Olaparib is in Phase 3 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The ongoing Phase 3 trial is recruiting patients to evaluate its safety and efficacy in combination with standard chemotherapy for advanced epithelial ovarian cancer.
Olaparib is being studied in one active Phase 3 clinical trial, identified as NCT06915025. This randomized, active-controlled trial is recruiting 500 female patients aged 18 years and older in the United States with newly diagnosed advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Olaparib is the drug being evaluated in the Phase 3 trial, and the trial title refers to IMNN-001 as the investigational agent. The trial is testing IMNN-001 in combination with standard chemotherapy, and Olaparib is the name associated with this drug candidate in the context of this development program.